Original InvestigationDialysisImmunogenicity of a Standard Trivalent Influenza Vaccine in Patients on Long-term Hemodialysis: An Open-Label Trial
Section snippets
Participants
During the 2003 to 2004 influenza season, 201 stable HD patients were enrolled from 2 different units (University Hospitals, Leuven, and Virga Jesse Hospital, Hasselt, Belgium). All patients were dialyzed thrice weekly for 4 hours with synthetic membranes. Patients treated with immunosuppressive drugs or with known allergy to chicken proteins were excluded. Forty-one hospital staff members were recruited as controls. The study was approved by the local ethics committee. All patients gave
Study Population
Baseline clinical characteristics of HD patients are listed in Table 1. HD patients were significantly older (67 ± 14 versus 56 ± 7 years; P < 0.001) and were more often vaccinated against influenza (81.7% versus 60.0%; P < 0.05) in the preceding influenza season compared with healthy volunteers. There were also proportionally more men in the HD cohort (60.7% versus 29.3%; P < 0.001). Patients with seroprotection against none of the influenza strains at baseline (n = 16) had significantly lower
Discussion
To the best of our knowledge, this study is the largest prospective study ever performed in HD patients evaluating antibody response after influenza vaccination and factors affecting this response. The major findings are as follows: (1) influenza vaccination confers high seroprotection rates (ranging from 81% to 87%) in HD patients, (2) the immune response to influenza vaccination is similar in HD patients and healthy volunteers, (3) a booster dose does not improve seroprotection rates, and (4)
Acknowledgements
Results presented in this report have been published previously in abstract format. Nephrol Dial Transplant 22:228, 2007.
Support: Part of this study was supported by an unrestricted grant from Roche Pharmaceuticals. The company did not take part in the design of the study, collection or analysis of the data, writing of the report, or the decision to publish the report.
Financial Disclosure: None.
References (40)
- et al.
Influenza vaccine delivery and effectiveness in end-stage renal disease
Kidney Int
(2003) - et al.
Antibody responses to influenza vaccination in patients with chronic renal failure
Kidney Int
(1978) - et al.
Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients
Vaccine
(2004) - et al.
Inter-method variability in PTH measurement: Implication for the care of CKD patients
Kidney Int
(2006) - et al.
Seroprotection rate, mean fold increase, seroconversion rate: Which parameter adequately expresses seroresponse to influenza vaccination?
Virus Res
(2004) - et al.
Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients
Am J Kidney Dis
(1997) - et al.
Factors influencing response to hepatitis B virus vaccination in hemodialysis patients
Transplant Proc
(2000) - et al.
The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients
Vaccine
(2004) - et al.
A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients
Am J Kidney Dis
(2001) - et al.
Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients
Kidney Int
(2005)
Effect of influenza vaccines in stimulating antibody in volunteers with prior immunity
Lancet
Influenza vaccination is efficacious and safe in renal transplant recipients
Am J Transplant
Immune function is impaired in iron-deficient, homebound, older women
Am J Clin Nutr
Iron deficiency and the immune response
Am J Clin Nutr
Trivalent influenza vaccine in patients on haemodialysis: Impaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components
Vaccine
Molecular aspects of T- and B-cell function in uremia
Kidney Int
Influenza vaccination in renal patients
Nephrol Dial Transplant
National surveillance of dialysis-associated diseases in the United States, 2001
Semin Dial
Vaccine recommendations for patients on chronic dialysisThe Advisory Committee on Immunization Practices and the American Academy of Pediatrics
Semin Dial
Active influenza immunization in hemodialysis patients: Comparison between single-dose and booster vaccination
Am J Nephrol
Cited by (60)
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
2022, Clinical Microbiology and InfectionWho and when to vaccinate against influenza
2020, International Journal of Infectious DiseasesCitation Excerpt :Most studies report lower seroprotection and seroconversion rates as well as lower geometric mean antibody titres after influenza vaccination in persons with end-stage renal disease compared to healthy individuals (Principi et al., 2015). Interestingly, Sharpé et al. found than more than 80% of persons receiving hemodialysis reached seroprotective levels after vaccination, which was comparable with the response observed in healthy individuals (Sharpé et al., 2009). In a study of patients with CKD undergoing dialysis in Korea, the seroconversion rate after MF59-adjuvanted influenza vaccine was significantly higher than after non-adjuvanted IIV at 1 month post-vaccination (47.7% versus 17.4% for A(H1N1), 42.0% versus 16.3% for A(H3N2), and 31.8% versus 7.0% for B), although the increase was only significant for type B in patients aged ≥65 years (33.3% versus 7.1% for B) (Noh et al., 2016).
Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccine Among Patients Receiving Maintenance Hemodialysis
2020, American Journal of Kidney DiseasesEradicating the Viral Triad in Hemodialysis Units
2019, Advances in Chronic Kidney Disease
Originally published online as doi: 10.1053/j.ajkd.2008.11.032 on April 2, 2009.
Trial registration: www.clinicaltrials.gov; study number: NCT00776750.